Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis

doi:10.1515/med-2016-0099

科研成果详情

题名	Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis
作者	Hong, Yan 2; Gui, Zhihong 1; Cai, Xiaoping 3; Lan, Lejian 1
发表日期	2016-01
发表期刊	OPEN MEDICINE 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Tripterygium glycosides Clinical efficacy Safety Diabetic nephropathy Meta-analysis
其他关键词	MANAGEMENT
摘要	The aim of this meta-analysis was to evaluate the clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy. Methods Through searching the PubMed and CNKI databases, the open published clinically controlled trials related to efficacy and safety of tripterygium glycosides in the treatment of stage IV diabetic nephropathy were collected. The pooled total efficacy, 24h urinary protein, serum creatinine and tripterygium glycosides related toxicity were calculated using Stata 11.0 software. Results Fourteen publications including 992 subjects (512 in the experimental group and 480 in the control group) were included in this study. Eight studies reported the total clinical efficacy comparing the experiment and control groups. No significant statistical heterogeneity was found in total efficacy (I-2=24.9%, p>0.05). Thus, the combined odds ratio (OR) was pooled by fixed effect model. The pooled OR=4.16 with its 95% CI 2.71 similar to 6.37 (p<0.05), which indicated the total efficacy in the experiment group, was significant higher than that of control group (p<0.05); Thirteen studies reported the post-treatment 24h urinary protein value. Statistical heterogeneity analysis indicated significant heterogeneity across studies (I-2=91.1%, p<0.05); that data was pooled by a random effects model. The combined standardized mean difference (SMD) was -1.55 with its 95% CI -2.06 +/- 1.03, (p<0.05). The results indicated that post-treatment 24h urinary protein in the experiment group was significant lower than that in control group (p<0.05); Ten studies reported the post-treatment serum creatinine. Significant heterogeneity existed across those studies (I-2=82.3%, p<0.05). Thereafter, the data was pooled by a random effect model. The combined standardized mean difference (SMD) was -0.24 with its 95% CI -0.40 +/- 0.09, (p<0.05). The results indicated that the post-treatment serum creatinine in experiment group was significant lower than that of control group (p<0.05); Eight studies reported tripterygium glycoside-associated toxicity such as liver function damage, gastrointestinal reactions and menstrual disorders. With no statistical heterogeneity among the studies, the data was pooled by fixed effect model. The pooled OR=6.42 (95% CI 2.23 +/- 18.48, p<0.05). The pooled results showed the tripterygium glycoside-associated toxicity incidence rate was significant higher in the experiment group than that of the control group (p<0.05); There were no publication bias for effect size of total efficacy, 24h urinary protein, and serum creatinine. However, for tripterygium glycoside-related toxicity, the publication bias was significant (t=-3.55, p<0.05). Conclusion The present evidence shows that tripterygium glycosides can improve clinical efficacy, reduce the 24h urinary protein and serum creatinine, but that they increase the tripterygium glycoside-related toxicity in treatment of stage IV diabetic nephropathy.
出版者	SCIENDO
出版地	WARSAW
ISSN	2391-5463
卷号	11 期号:1 页码:611-617
DOI	10.1515/med-2016-0099
页数	7
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
WOS记录号	WOS:000394240400033
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	28352854
PMC记录号	PMC5329886
SCOPUSEID	2-s2.0-85013116220
通讯作者地址	[Lan, Lejian]Department of Nephrology,Sixth Affiliated Hospital of Wenzhou Medical University,People's Hospital of Lishui City,Zhejiang Province,323000,China
Scopus学科分类	Medicine (all)
引用统计	被引频次：15[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/14210
专题	温州医科大学其他_附属第五医院（丽水市中心医院）
通讯作者	Lan, Lejian
作者单位	1.Department of Nephrology,Sixth Affiliated Hospital of Wenzhou Medical University,People's Hospital of Lishui City,Zhejiang Province,323000,China; 2.Department of Clinical Pharmacy,Fifth Affiliated Hospital of Wenzhou Medical University,Lishui Central Hospital,Zhejiang Province,323000,China; 3.Department of Respiratory,Sixth Affiliated Hospital of Wenzhou Medical University,People's Hospital of Lishui City,Zhejiang Province,323000,China
第一作者单位	其他_附属第五医院（丽水市中心医院）
通讯作者单位	温州医科大学
第一作者的第一单位	其他_附属第五医院（丽水市中心医院）
推荐引用方式 GB/T 7714	Hong, Yan,Gui, Zhihong,Cai, Xiaoping,et al. Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis[J]. OPEN MEDICINE,2016,11(1):611-617.
APA	Hong, Yan, Gui, Zhihong, Cai, Xiaoping, & Lan, Lejian. (2016). Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis. OPEN MEDICINE, 11(1), 611-617.
MLA	Hong, Yan,et al."Clinical efficacy and safety of tripterygium glycosides in treatment of stage IV diabetic nephropathy: A meta-analysis".OPEN MEDICINE 11.1(2016):611-617.